CD8A and neoplasm: Advances in the field of cancer immunology have led to the advent of novel immunotherapeutics that reactivate tumor-infiltrating CD8+ cytotoxic T lymphocytes (CTLs) against late-stage metastatic cancers such as melanoma (Mellman et al., 2011).